Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK

Shamez Ladhani*, Nicholas Andrews, Mary E. Ramsay

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)

Abstract

Pneumococcal conjugate vaccines (PCVs) are highly effective in preventing invasive and non-invasive pneumococcal infections in all age groups through a combination of direct and indirect protection. In many industrialised countries with established PCV programmes, the maximum benefit of the PCV programme has already been achieved, with most cases now due to non-PCV serotypes. On Jan 1, 2020, the UK changed its childhood pneumococcal immunisation programme from a two-dose infant priming schedule with the 13-valent PCV at 8 and 16 weeks after birth, to a single priming dose at 12 weeks after birth, while retaining the 12-month booster. This decision was made after reviewing the evidence from surveillance data, clinical trials, epidemiological analyses, vaccine effectiveness estimates, and modelling studies to support the reduced schedule. In this Review, we summarise the epidemiology of pneumococcal disease in the UK, the evidence supporting the decision to implement a reduced schedule, and the national and global implications of the proposed schedule.

Original languageEnglish
Pages (from-to)e93-e102
Number of pages10
JournalThe Lancet Infectious Diseases
Volume21
Issue number4
DOIs
Publication statusPublished - Apr 2021

Bibliographical note

Funding Information:
SNL does contract research on behalf of St George's University of London and Public Health England for vaccine manufacturers (GlaxoSmithKline, Pfizer, and Sanofi Pasteur) but does not receive any personal remuneration. The Immunisation and Countermeasures Division at Public Health England provides vaccine manufacturers with postmarketing surveillance reports on meningococcal, Haemophilus influenzae, and pneumococcal infections, where the companies are required to submit to the UK Licensing Authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. MER reports grants from GSK, Pfizer, Vaccine Manufacturers, outside the submitted work. NA declares no competing interests.

Publisher Copyright:
© 2021 Elsevier Ltd

Fingerprint

Dive into the research topics of 'Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK'. Together they form a unique fingerprint.

Cite this